CN111051345A - 柄蛋白-4结合蛋白及其使用方法 - Google Patents

柄蛋白-4结合蛋白及其使用方法 Download PDF

Info

Publication number
CN111051345A
CN111051345A CN201880049820.6A CN201880049820A CN111051345A CN 111051345 A CN111051345 A CN 111051345A CN 201880049820 A CN201880049820 A CN 201880049820A CN 111051345 A CN111051345 A CN 111051345A
Authority
CN
China
Prior art keywords
seq
antibody
nectin
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049820.6A
Other languages
English (en)
Chinese (zh)
Inventor
K·J·M·莫里森
F·多纳特
P·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to CN202010492265.3A priority Critical patent/CN111675761B/zh
Publication of CN111051345A publication Critical patent/CN111051345A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201880049820.6A 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法 Pending CN111051345A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010492265.3A CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515454P 2017-06-05 2017-06-05
US62/515,454 2017-06-05
PCT/US2018/035840 WO2018226578A1 (en) 2017-06-05 2018-06-04 Nectin-4-binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010492265.3A Division CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Publications (1)

Publication Number Publication Date
CN111051345A true CN111051345A (zh) 2020-04-21

Family

ID=64566092

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880049820.6A Pending CN111051345A (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法
CN202010492265.3A Active CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010492265.3A Active CN111675761B (zh) 2017-06-05 2018-06-04 柄蛋白-4结合蛋白及其使用方法

Country Status (10)

Country Link
US (1) US11292837B2 (enExample)
EP (1) EP3635013A4 (enExample)
JP (1) JP7168590B2 (enExample)
KR (1) KR102723905B1 (enExample)
CN (2) CN111051345A (enExample)
BR (1) BR112019025513A2 (enExample)
CA (1) CA3065514A1 (enExample)
MX (1) MX2019014318A (enExample)
TW (1) TWI870338B (enExample)
WO (1) WO2018226578A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110951712A (zh) * 2019-05-31 2020-04-03 江南大学 一种脂肪酶突变体及其在去污方面的应用
WO2024251260A1 (zh) 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
JP2022551537A (ja) * 2019-10-07 2022-12-09 ユニヴェルシテ デクス－マルセイユ ネクチン－４に対する特異性を有する抗体及びその使用
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
WO2021257525A1 (en) * 2020-06-18 2021-12-23 Bioatla, Inc. Conditionally active anti-nectin-4 antibodies
EP4168039A4 (en) * 2020-06-19 2024-12-04 Agensys, Inc. MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC)
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
GEAP202516662A (en) * 2020-09-16 2025-02-10 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anti-nectin-4 antibody, conjugate including same, and application thereof
JP2024501121A (ja) * 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2022228406A1 (zh) * 2021-04-26 2022-11-03 江苏恒瑞医药股份有限公司 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
JP7820532B2 (ja) * 2022-01-12 2026-02-25 ナビ バイオ－セラピューティクス，インコーポレイティッド ネクチン細胞接着分子４に特異的な抗体及びその使用
US20250205353A1 (en) 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
EP4310101A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibodies and antibody-drug conjugates
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111076A1 (en) * 2004-05-12 2005-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) as a marker for cancer prognosis
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010067487A1 (en) 2008-12-12 2010-06-17 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP3311173A2 (en) * 2015-06-18 2018-04-25 Thomas Mole Herd Methods of characterising cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110951712A (zh) * 2019-05-31 2020-04-03 江南大学 一种脂肪酶突变体及其在去污方面的应用
WO2024251260A1 (zh) 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途

Also Published As

Publication number Publication date
JP7168590B2 (ja) 2022-11-09
EP3635013A4 (en) 2021-02-24
CA3065514A1 (en) 2018-12-13
US20200231670A1 (en) 2020-07-23
BR112019025513A2 (pt) 2020-06-23
KR102723905B1 (ko) 2024-10-31
MX2019014318A (es) 2020-08-13
TW201902922A (zh) 2019-01-16
JP2020522261A (ja) 2020-07-30
CN111675761B (zh) 2023-10-20
EP3635013A1 (en) 2020-04-15
WO2018226578A8 (en) 2019-05-31
KR20200024788A (ko) 2020-03-09
CN111675761A (zh) 2020-09-18
TWI870338B (zh) 2025-01-21
RU2019144030A3 (enExample) 2021-12-28
US11292837B2 (en) 2022-04-05
WO2018226578A1 (en) 2018-12-13
RU2019144030A (ru) 2021-07-09

Similar Documents

Publication Publication Date Title
CN111675761B (zh) 柄蛋白-4结合蛋白及其使用方法
US12378312B2 (en) Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof
US20230272076A1 (en) PD-1 Binding Proteins and Methods of Use Thereof
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
US20210380675A1 (en) Il-36 antibodies and uses thereof
HK40037283A (en) Nectin-4 binding proteins and methods of use thereof
RU2805252C2 (ru) Белки, связывающие нектин-4, и способы их применения
HK40026608A (en) Nectin-4 binding proteins and methods of use thereof
HK40037283B (zh) 柄蛋白-4结合蛋白及其使用方法
US20250189530A1 (en) Btn1a1 binding proteins and methods of use thereof
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825B (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026608

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200421